Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 19 studies | 31% ± 10% | |
brain | 18 studies | 33% ± 17% | |
peripheral blood | 14 studies | 27% ± 9% | |
eye | 9 studies | 30% ± 14% | |
intestine | 8 studies | 27% ± 9% | |
kidney | 8 studies | 24% ± 5% | |
heart | 5 studies | 22% ± 4% | |
lymph node | 5 studies | 29% ± 13% | |
liver | 5 studies | 42% ± 24% | |
bone marrow | 4 studies | 28% ± 12% | |
uterus | 4 studies | 40% ± 19% | |
breast | 4 studies | 31% ± 14% | |
prostate | 4 studies | 35% ± 7% | |
adipose | 4 studies | 27% ± 4% | |
pancreas | 3 studies | 40% ± 13% | |
placenta | 3 studies | 47% ± 9% | |
esophagus | 3 studies | 27% ± 14% | |
skin | 3 studies | 19% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 4297.77 | 1445 / 1445 | 100% | 139.96 | 183 / 183 |
lung | 100% | 7153.46 | 578 / 578 | 100% | 121.35 | 1155 / 1155 |
stomach | 100% | 3914.48 | 359 / 359 | 100% | 128.21 | 286 / 286 |
intestine | 100% | 4622.05 | 966 / 966 | 100% | 123.29 | 526 / 527 |
breast | 100% | 4422.58 | 459 / 459 | 100% | 125.78 | 1113 / 1118 |
ovary | 100% | 4101.67 | 180 / 180 | 100% | 76.44 | 428 / 430 |
bladder | 100% | 3830.52 | 21 / 21 | 99% | 96.63 | 500 / 504 |
thymus | 100% | 5376.51 | 653 / 653 | 99% | 100.30 | 600 / 605 |
brain | 99% | 2914.86 | 2620 / 2642 | 100% | 84.12 | 705 / 705 |
prostate | 100% | 4101.80 | 245 / 245 | 99% | 95.96 | 495 / 502 |
uterus | 100% | 3977.58 | 170 / 170 | 98% | 101.74 | 452 / 459 |
pancreas | 99% | 2217.38 | 326 / 328 | 98% | 85.03 | 175 / 178 |
kidney | 100% | 3850.33 | 89 / 89 | 97% | 67.08 | 875 / 901 |
skin | 100% | 5917.40 | 1809 / 1809 | 97% | 95.31 | 458 / 472 |
adrenal gland | 100% | 5129.59 | 258 / 258 | 97% | 56.73 | 222 / 230 |
liver | 100% | 2706.76 | 226 / 226 | 92% | 42.80 | 373 / 406 |
adipose | 100% | 4685.10 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3047.96 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 129.51 | 29 / 29 |
spleen | 100% | 5902.13 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 24.12 | 1 / 1 |
muscle | 99% | 2132.55 | 796 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 5328.82 | 916 / 929 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 80.38 | 44 / 45 |
heart | 95% | 2131.03 | 817 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 86% | 37.90 | 69 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0018105 | Biological process | peptidyl-serine phosphorylation |
GO_0012501 | Biological process | programmed cell death |
GO_0007059 | Biological process | chromosome segregation |
GO_0006260 | Biological process | DNA replication |
GO_0006338 | Biological process | chromatin remodeling |
GO_0032922 | Biological process | circadian regulation of gene expression |
GO_0007623 | Biological process | circadian rhythm |
GO_0006265 | Biological process | DNA topological change |
GO_0040016 | Biological process | embryonic cleavage |
GO_0016310 | Biological process | phosphorylation |
GO_0009410 | Biological process | response to xenobiotic stimulus |
GO_0005730 | Cellular component | nucleolus |
GO_0032993 | Cellular component | protein-DNA complex |
GO_0000228 | Cellular component | nuclear chromosome |
GO_0043204 | Cellular component | perikaryon |
GO_0005654 | Cellular component | nucleoplasm |
GO_0001650 | Cellular component | fibrillar center |
GO_0000932 | Cellular component | P-body |
GO_0001673 | Cellular component | male germ cell nucleus |
GO_0005634 | Cellular component | nucleus |
GO_0003677 | Molecular function | DNA binding |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0008301 | Molecular function | DNA binding, bending |
GO_0019904 | Molecular function | protein domain specific binding |
GO_0003682 | Molecular function | chromatin binding |
GO_0003697 | Molecular function | single-stranded DNA binding |
GO_0003690 | Molecular function | double-stranded DNA binding |
GO_0004674 | Molecular function | protein serine/threonine kinase activity |
GO_0097100 | Molecular function | supercoiled DNA binding |
GO_0003917 | Molecular function | DNA topoisomerase type I (single strand cut, ATP-independent) activity |
GO_0005524 | Molecular function | ATP binding |
GO_0003723 | Molecular function | RNA binding |
GO_0005515 | Molecular function | protein binding |
Gene name | TOP1 |
Protein name | DNA topoisomerase 1 (EC 5.6.2.1) (DNA topoisomerase I) TOP1 protein DNA topoisomerase I (EC 5.6.2.1) (DNA topoisomerase 1) DNA topoisomerase I |
Synonyms | |
Description | FUNCTION: Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a single-strand break via transesterification at a target site in duplex DNA. The scissile phosphodiester is attacked by the catalytic tyrosine of the enzyme, resulting in the formation of a DNA-(3'-phosphotyrosyl)-enzyme intermediate and the expulsion of a 5'-OH DNA strand. The free DNA strand then rotates around the intact phosphodiester bond on the opposing strand, thus removing DNA supercoils. Finally, in the religation step, the DNA 5'-OH attacks the covalent intermediate to expel the active-site tyrosine and restore the DNA phosphodiester backbone (By similarity). Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells. Involved in the circadian transcription of the core circadian clock component BMAL1 by altering the chromatin structure around the ROR response elements (ROREs) on the BMAL1 promoter. . FUNCTION: Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a single-strand break via transesterification at the specific target site 5'-[CT]CCTTp site in duplex DNA. The scissile phosphodiester is attacked by the catalytic tyrosine of the enzyme, resulting in the formation of a DNA-(3'-phosphotyrosyl)-enzyme intermediate and the expulsion of a 5'-OH DNA strand. The free DNA strand then undergoes passage around the unbroken strand thus removing DNA supercoils. Finally, in the religation step, the DNA 5'-OH attacks the covalent intermediate to expel the active-site tyrosine and restore the DNA phosphodiester backbone. . FUNCTION: Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a single-strand break via transesterification at the specific target site 5'-[CT]CCTTp site in duplex DNA. The scissile phosphodiester is attacked by the catalytic tyrosine of the enzyme, resulting in the formation of a DNA-(3'-phosphotyrosyl)-enzyme intermediate and the expulsion of a 5'-OH DNA strand. The free DNA strand then undergoes passage around the unbroken strand thus removing DNA supercoils. Finally, in the religation step, the DNA 5'-OH attacks the covalent intermediate to expel the active-site tyrosine and restore the DNA phosphodiester backbone. . |
Accessions | ENST00000361337.3 ENST00000680945.1 B9EG90 P11387 ENST00000681113.1 A0A7P0T9R7 Q6NWZ5 Q6PK95 A0A7P0T852 |